Valion Bio completes 200-liter Entolimod production run to supply ongoing study
VBIO•Valion Bio completed a 200-liter Entolimod production run to supply its ongoing study. The May-June 2026 run improved productivity, and the drug substance met all predefined quality acceptance criteria.
1. Production run completed
Valion Bio said it completed a 200-liter Entolimod production run supplying its ongoing Armed Forces Radiobiology Research Institute study. The May-June 2026 run improved productivity, and the drug substance met all predefined quality acceptance criteria.
2. Study and development
Entolimod is being developed for acute radiation syndrome under the FDA’s Animal Rule and has Fast Track and Orphan Drug designations. The study is fully funded by the National Institute of Allergy and Infectious Diseases through an interagency agreement.




